Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 14/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592161 | 0.89 | PKM (0.59) | PKMBRAF | |
| SCHEMBL3596236 | 0.87 | PKM (0.69) | PKMBRAF | |
| SCHEMBL3594209 | 0.86 | BRAF (0.63) | PKMBRAFKDM4EALDH1A1MAOA | |
| SCHEMBL3596803 | 0.85 | PKM (0.61) | PKMBRAFMAOAMAOB | |
| SCHEMBL3594488 | 0.85 | BRAF (0.64) | PKMBRAF | |
| SCHEMBL3599747 | 0.84 | PKM (0.58) | PKMBRAF | |
| SCHEMBL3586945 | 0.84 | BRAF (0.77) | PKMBRAF | |
| SCHEMBL3585431 | 0.84 | PKM (0.67) | PKMBRAFMAOAMAOB | |
| SCHEMBL3603481 | 0.82 | BRAF (0.61) | PKMBRAFMAOA | |
| SCHEMBL3584944 | 0.82 | PKM (0.59) | PKMBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795249-B2 | Certain pyrazoline derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | claimed |
| US-7795249-B2 | Certain pyrazoline derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795249-B2 | Certain pyrazoline derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080171754-A1 | Certain pyrazoline derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080171754-A1 | Certain pyrazoline derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171754-A1 | Certain pyrazoline derivatives with kinase inhibitory activity | MAP3K5, MAP4K5, MAP3K20 | PKM 315/4885BRAF 123/4885KDM4E 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.